Acute Myeloid Leukemia | Unmet Need | First-Line Intensive-Induction-Eligible | US/FR/DEU/UK | 2023

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but recent drug approvals suggest a shift toward targeted agents. Approximately 70% of patients treated with cytotoxic chemotherapy achieve complete remission. Nevertheless, the five-year relative survival rate is only 30.5%. In this report, we focus on the unmet need in the first-line treatment of intensive-induction-eligible AML. These patients currently receive cytotoxic chemotherapy, with or without biomarker-driven targeted therapies (such as Mylotarg and Rydapt) or the topoisomerase II inhibitor Vyxeos.

QUESTIONS ANSWERED

What treatment drivers and goals are most important to surveyed hematologist-oncologists when selecting a first-line therapy for intensive-induction-eligible AML?
How do key currently available regimens, including Vyxeos or Rydapt in combination with intensive chemotherapy, perform in terms of key attributes?
What are the greatest unmet needs and most attractive opportunities in the first-line treatment of intensive-induction-eligible AML?
What tradeoffs are surveyed hematologist-oncologists willing to make for new and emerging therapies to treat this subpopulation of AML?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 62 U.S. and 31 European hematologist-oncologists fielded in December 2022.

Key companies: Pfizer, Novartis, Jazz Pharmaceuticals

Key drugs: Mylotarg, Rydapt, Vyxeos, cytarabine, daunorubicin, fludarabine, G-CSF, and idarubicin

Contact sales account_box

Report

Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…

north_east

Report

Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)

Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…

north_east

Report

Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)

Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…

north_east

Report

Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)

Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…

north_east

Report

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…

north_east

Product logins

Acute Myeloid Leukemia | Unmet Need | First-Line Intensive-Induction-Eligible | US/FR/DEU/UK | 2023

Related Market Assessment Reports

Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)

Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)

Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Follow us

Contact us